Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 67Ovarian Neoplasms 8Neoplasm Metastasis 8Endometrial Neoplasms 6Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Hereditary Sensory and Autonomic Neuropathies 4Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Squamous Cell Carcinoma of Head and Neck 3Neoplasms by Site 3Colorectal Neoplasms 3Breast Diseases 3Small Cell Lung Carcinoma 2Melanoma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Head and Neck Neoplasms 2Uterine Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Salivary Gland Neoplasms 1Recurrence 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Locoregional Recurrence 1

Interventions

Letrozole 2palbociclib 1Fulvestrant 1Diet, Ketogenic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Estrogen Receptor-positive Breast Cancer × Fulvestrant × 90 days × Clear all
NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡